Oxford BioMedica plc with ticker (LON:OXB) now has a potential downside of -3.8% according to Deutsche.OXB.LDeutsche set a target price of 380 GBX for the company, which when compared to..
Oxford BioMedica plc with ticker (LON:OXB) now has a potential downside of -5.9% according to Deutsche.OXB.LDeutsche set a target price of 380 GBX for the company, which when compared to..
Oxford BioMedica plc with ticker (LON:OXB) now has a potential downside of -5.0% according to Deutsche.OXB.LDeutsche set a target price of 380 GBX for the company, which when compared to..
Oxford BioMedica plc with ticker (LON:OXB) now has a potential downside of -9.9% according to Numis.Numis set a target price of 180 GBX for the company, which when compared to..
Oxford BioMedica plc with ticker (LON:OXB) now has a potential downside of -4.6% according to Numis.Numis set a target price of 180 GBX for the company, which when compared to..
Oxford BioMedica plc with ticker (LON:OXB) now has a potential upside of 3.3% according to Liberum Capital.Liberum Capital set a target price of 310 GBX for the company, which when..
Oxford BioMedica plc with ticker (LON:OXB) now has a potential upside of 3.7% according to Liberum Capital.Liberum Capital set a target price of 310 GBX for the company, which when..
Oxford Biomedica plc (LON:OXB), a leading cell and gene therapy group, has announced that it has entered into an agreement with Homology Medicines Inc. (Nasdaq:FIXX) pursuant to which Oxford Biomedica..
Oxford Biomedica plc (LON:OXB), a leading cell and gene therapy group, has today announced its preliminary results for the year ended 31st December 2020. John Dawson, Chief Executive Officer of..
Oxford BioMedica (OXB) is a specialist, advanced therapy, viral-vector biopharma company. It offers vector manufacturing and development services, while developing proprietary drug candidates, with its LentiVector® platform. 2018 saw significant..
Oxford BioMedica (LON: OXB) is a specialist, advanced therapy, viral-vector biopharma company. It offers vector manufacturing and development services, while developing proprietary drug candidates, with its LentiVector® platform. 2018 saw..
Oxford BioMedica (LON:OXB) is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, while retaining proprietary drug candidates. OXB will also receive royalties on commercial..
Oxford BioMedica (LON:OXB) is a specialist, advanced-therapy, lentivirus vector biopharma company. It offers vector manufacturing and development services and has a proprietary drug pipeline. In addition to LentiVector® service contracts,..
Oxford BioMedica Plc (LON:OXB) is a specialist advanced-therapy lentivirus vector biopharma company. It offers vector manufacturing and development services, and also has a proprietary drug pipeline. In addition to LentiVector®..
Oxford Biomedica plc (LON:OXB) is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining proprietary drug candidates. OXB will also receive royalties on..
Oxford BioMedica plc (LON:OXB) is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees,..
